In 2005, the U.S. Food and Drug Administration (FDA) informed that patients with homozygous UGT1A1*28 are at increased risk of severe neutropenia following initiation of irinotecan treatment20. The gene discussed is UGT1A1; the disease is Decreased total neutrophil count.